期刊文献+

化学发光法定量检测抗ENA抗体和抗dsDNA抗体临床性能评价 被引量:2

Clinical performance evaluation to chemiluminescence immunoassay for the detection of anti-ENA and anti-dsDNA
下载PDF
导出
摘要 目的分析SMART-6500化学发光检测平台针对抗可提取物核抗原抗体(抗ENA抗体)及抗双链DNA抗体(抗dsDNA抗体)的定量检测性能。方法参照美国临床和实验室标准化协会(CLSI)EP系列文件的要求,分析SMART-6500化学发光检测平台检测抗ENA抗体和抗dsDNA抗体的精密度、线性范围、生物参考区间和方法学对比等性能指标。应用世界卫生组织(WHO)标准物质(NIBCS代码:15/174)对抗dsDNA抗体检测项目开展量值溯源研究。结果抗ENA抗体和抗dsDNA抗体的批内精密度变异系数(CV)和批间精密度CV分别处于2.16%~6.67%和4.70%~12.71%;线性范围R值处于0.9926~0.9980;方法学对比显示所有检测项目的总符合率均大于90%。抗dsDNA抗体国际标准物质经SMART-6500检测结果为24.67U/mL。结论SMART-6500化学发光检测平台在检测抗ENA抗体和抗dsDNA抗体时,表现出良好的精密度和线性范围,与酶联免疫吸附试验的检测结果具有较高的符合率,因此可满足免疫临床对于抗ENA抗体和抗dsDNA抗体定量检测的需要。 Objective To evaluate the feature of quantitative measurement to anti-ENA antibody and anti-dsDNA with SMART-6500 chemiluminescence immunoassay. Methods According to the requirements of Clinical and Laboratory Standards Institute (CLSI) EP series documents,the performance indicators of SMART-6500 Chemiluminescence Detection Platform for detecting anti-ENA and anti-dsDNA,such as precision,linear range,biological reference range and methodological comparison,were analyzed.The quantitative traceability of anti dsDNA detection project was studied by using World Health Organization (WHO) reference material (NIBCS code:15/174). Results The coefficient variation (CV) for each assay from the precision study ranged from 2.16% to 6.67%(within-run) and from 4.70% to 12.71%(intra-day),respectively.The linearity analysis showed linearity regression value within 0.992 6-0.998 0 for each assay.Methodological comparison showed that the total coincidence rate of all test items was more than 90%.Anti-dsDNA international standard substance was detected by SMART-6500 was 24.67 U/mL. Conclusion SMART-6500 Chemiluminescence Detection Platform shows good precision and linearity in detecting anti-ENA and anti-dsDNA,and has a high coincidence rate with enzyme linked immunosorbent assay detection results,so it can meet the needs of immunology clinic for quantitative detection of anti-ENA and anti-dsDNA.
作者 柳晓琴 崔亚利 沈川 甘春玉 段义飞 彭磊文 李文胜 LIU Xiaoqin;CUI Yali;SHEN Chuan;GAN Chunyu;DUAN Yifei;PENG Leiwen;LI Wensheng(Department of Clinical Laboratory,West China Second University Hospital of Sichuan University,Chengdu,Sichuan 610041,China;Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University),Ministry of Education,Chengdu,Sichuan 610041,China)
出处 《国际检验医学杂志》 CAS 2019年第12期1475-1479,1485,共6页 International Journal of Laboratory Medicine
关键词 SMART-6500 化学发光 抗ENA抗体 抗DSDNA抗体 定量检测 性能评价 SMART-6500 chemiluminescence immunoassay anti-ENA antibody anti-dsDNA quantitative measurement performance evaluation
  • 相关文献

参考文献3

二级参考文献47

  • 1Guyatt GH, Oxman AD, Vist GE, et ah GRADE: an emerging consensus on rating quality of evidence and strength of recom- mendations[J]. BMJ, 2008, 336: 924-926.
  • 2Damoiseaux JG, Tervaert JW. From ANA to ENA: how to proceed?[J]. Autoimmun Rev, 2006, 5: 10-17.
  • 3Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1982, 25: 1271-1277.
  • 4Linnik MD, Hu JZ, Heilbrunn KR, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2005, 52: 1129-1137.
  • 5Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies[J]. Lupus, 2006, 15: 408-411.
  • 6Akhter E, Burlingame RW, Seaman AL, et al. Anti-Clq anti-bodies have higher correlation with flares of lupus nephritis than other serum markers[J]. Lupus, 2011, 20: 1267-1274.
  • 7Mok CC, Tang SS, To CH, et al. thromboembolism in systemic lupus of three ethnic groups[J]. Arthritis 2782. Incidence and risk factors of erythematosus: a comparison Rheum, 2005, 52: 2774-.
  • 8Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic anti- bodies[J]. Lancet, 2006, 368: 404-418.
  • 9Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62: 2569-2581.
  • 10Van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibod- ies: the past, the present and the future[J]. Nat Rev Rheumatol, 2011, 7: 391-398.

共引文献67

同被引文献13

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部